Pharmacist e-consults to improve lung medicines and care for people with HIV
Tests pharmacist-led electronic advice on lung medicines and vaccines in adults with HIV.
Plain-language title generated from the registry record
Registry title: Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
Key facts
- Where
- Boise, Minneapolis, and Seattle, United StatesSee the 3 sites
Where in United States
- Boise VA Medical CenterBoise, United StatesNot yet recruiting
- Minneapolis VA Health Care SystemMinneapolis, United StatesNot yet recruiting
- VA Puget Sound Health Care SystemSeattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seattle Institute for Biomedical and Clinical Research
- Trial code
- NCT07507435
- Record updated
- 9 November 2026
- Original description
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs).Read full original descriptionShow less
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults (OPTIMIZE Lung-HIV)
People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs).
OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate.
The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.
Inclusion: PWH with an active prescription of ART any time in past 6 months and <200 copies/mL within past 12 months, actively receiving care at the VA, and one of the following:; Actively smoking; Prescribed ICS for >90 days; Prescribed a PPI for >90 days.
Exclusion: If a non-VA provider is the main primary care or HIV provider; Enrolled in palliative care or hospice; Are currently participating in a separate ongoing interventional clinical trial.